Kalinowski Jonathan, Tal Oren, Reid Jake, Munro John, Moran Matthew, Armstrong Andrea, Enger Shirin A
Medical Physics Unit, Department of Oncology, Faculty of Medicine, McGill University, Montréal, Québec, Canada.
Lady Davis Institute for Medical Research, Jewish General Hospital, Montréal, Québec, Canada.
Med Phys. 2025 Sep;52(9):e18088. doi: 10.1002/mp.18088.
Se ( 120 days, 215 keV) offers advantages over Ir ( 74 days, 360 keV) as a high dose rate brachytherapy source due to its lower gamma energy and longer half-life. Despite its widespread use in industrial gamma radiography, a Se brachytherapy source has yet to be manufactured.
A novel Se-based source design with a vanadium diselenide core, titled the SeCure source, was proposed. This study aimed to evaluate the feasibility of this source design for dosimetry and manufacturability purposes and to develop an activated prototype source.
The source was modeled and integrated into the Monte Carlo-based treatment planning system RapidBrachyMCTPS, where its TG-43U1 parameters, photon spectrum, and broad beam first half-value layers (HVL) and tenth-value layers (TVL) in lead, tungsten, and concrete were calculated. A prototype source was manufactured, and the vanadium diselenide content of the capsule was verified with neutron radiography. The source was then activated to a nominal activity of mCi at the McMaster Nuclear Reactor. The activity was measured with two separate dose calibrators. Gamma spectroscopy was used to characterize any activated radioactive contaminants in the source, and wipe testing was performed to check for any leakage of Se from the encapsulation.
The SeCure source's TG-43U1 parameters were computed, showing that times the activity of Se is required relative to Ir to achieve the same dose rate in water at (1 cm, 90 ). The mean spectral energy of the source is keV, resulting in reduced first half-value and tenth-value layers relative to Ir in attenuating materials. For example, the was reduced from mm to mm in lead, from mm to mm in tungsten, and from mm to mm in concrete. The activated source achieved the desired activity, indicated as mCi and mCi at the end of irradiation on the two dose calibrators. All identified radionuclide contaminants decaying below of the Se activity after 5 days post-irradiation. Wipe testing only identified radioactive contaminants present in activated titanium, with only mCi of detected 72 h post-irradiation, indicating that the integrity of the encapsulation was maintained.
The SeCure design possesses the dosimetric, spectral, and physical properties necessary for a feasible high dose rate brachytherapy source. Next, manufacturing of a high-activity SeCure source will be pursued.
作为一种高剂量率近距离治疗源,硒(半衰期120天,γ能量215keV)相较于铱(半衰期74天,γ能量360keV)具有优势,因其γ能量较低且半衰期更长。尽管硒在工业γ射线照相中广泛应用,但硒近距离治疗源尚未制造出来。
提出一种以二硒化钒为核心的新型硒基源设计,即SeCure源。本研究旨在评估这种源设计用于剂量测定和可制造性的可行性,并开发一个活化的原型源。
对该源进行建模并集成到基于蒙特卡洛的治疗计划系统RapidBrachyMCTPS中,计算其TG - 43U1参数、光子能谱以及在铅、钨和混凝土中的宽束第一半价层(HVL)和第十值层(TVL)。制造了一个原型源,并用中子射线照相法验证了胶囊中二硒化钒的含量。然后在麦克马斯特核反应堆将该源活化至标称活度mCi。用两个独立的剂量校准器测量活度。用γ能谱法表征源中任何活化的放射性污染物,并进行擦拭试验以检查硒是否从封装中泄漏。
计算了SeCure源的TG - 43U1参数,表明在水中(1cm,90°)要达到相同剂量率,硒的活度需要是铱的倍。该源的平均能谱能量为keV,在衰减材料中,相对于铱,其第一半价层和第十值层减小。例如,在铅中从mm减小到mm,在钨中从mm减小到mm,在混凝土中从mm减小到mm。活化后的源达到了所需活度,在两个剂量校准器上照射结束时分别显示为mCi和mCi。所有识别出的放射性核素污染物在辐照后5天内衰变至硒活度的以下。擦拭试验仅识别出活化钛中存在的放射性污染物,辐照后72小时仅检测到mCi的,表明封装的完整性得以保持。
SeCure设计具备作为一种可行的高剂量率近距离治疗源所需的剂量学、能谱和物理特性。接下来,将致力于制造高活度的SeCure源。